Physician profile
Frances A Clark
NPI 1285978460
$17,881.34
in general payments reported to CMS, 2019-2025
27 companies · $2,602 in 2025
The $2,602 reported for 2025 was more than what 94% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,558 · 2022: $3,135 · 2023: $3,358 · 2024: $2,228 · 2025: $2,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,500 · Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,500.00 |
| Food and Beverage | $1,688.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,248.61 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.80 | 2021-2023 | Xifaxan, Trulance, Plenvu |
| Evoke Pharma, INC. | $380.84 | 2021-2023 | Gimoti |
| Janssen Biotech, INC. | $331.61 | 2021-2023 | Stelara |
| Ironwood Pharmaceuticals, INC | $195.16 | 2021-2023 | Linzess |
| Genzyme Corporation | $173.89 | 2022 | |
| Novo Nordisk INC | $122.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.23 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $121.13 | 2025 | Camzyos |
| Qol Medical, LLC | $91.27 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $74.77 | 2021-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $61.43 | 2021-2025 | Glassia |
| Merck Sharp & Dohme LLC | $59.39 | 2021-2022 | |
| Redhill Biopharma INC. | $50.81 | 2021-2022 | |
| Scpharmaceuticals INC. | $48.13 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $45.87 | 2025 | Overstitch Endoscopic Suturing System, X-Tack Endoscopic Helix Tacking System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.60 | 2025 | Lifevest |
| Nestle Healthcare Nutrition INC. | $38.89 | 2021-2022 | |
| Amgen INC. | $35.66 | 2023 | Amjevita, Avsola |
| Intercept Pharmaceuticals, INC. | $29.73 | 2022 | |
| Celgene Corporation | $29.46 | 2022 | |
| Ardelyx, INC. | $21.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.37 | 2023 | Dupixent |
| Fresenius Kabi USA, LLC | $12.90 | 2023 | |
| Daiichi Sankyo INC. | $11.97 | 2021 | |
| Organon LLC | $11.59 | 2022 | |
| Cvrx, INC. | $9.63 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.